Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis

Wang, Yanqiu; Jiang, Tao; Jiang, Mingyan; Shuijing, Gu

doi:10.1186/s12885-019-5385-y

Cited by 16 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study quality in relation to prognosis was judged by the Newcastle-Ottawa Scale (NOS) [24], wherein the risk regarding study selection, comparability, and outcome were assessed. A study was deemed to be of high quality when the QUADAS II score was ≥4 stars, and ≥ 6 stars for the NOS checklist [25].…”

Section: Methodsmentioning

confidence: 99%

“…HR and 95%CI were combined based on multivariate Cox hazard regression analysis, and the random effect model was chosen when significant heterogeneity was observed. Sensitivity and meta-regression tests were used to identify the underlying causes of heterogeneity [25]. Publication bias was quantitatively judged by Deeks’ funnel plot asymmetry test, Begg’s and Egger’s tests, and P < 0.05 was considered statistically significant.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer

Zhang

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

Background Circular RNAs (circRNAs) have emerged as a special subset of endogenous RNAs that are implicated in tumorigenesis and cancer progression. Herein we aim to carry out a meta-analysis to evaluate the clinicopathologic, diagnostic and prognostic significance of circRNA expression in colorectal cancer (CRC). Methods A systematic search of online databases was performed for original articles published in English, which investigated the diagnostic accuracy, prognostic utility, and clinicopathologic association of circRNA(s) in CRC. Data were strictly extracted and study bias was judged using the Quality Assessment for Studies of Diagnostic Accuracy II (QUADAS II) and Newcastle-Ottawa Scale (NOS) checklists. Results A total of 13 studies, involving 1430 patients with CRC, were included in the meta-analysis. The clinicopathologic study showed that abnormally expressed circRNAs were correlated with tumor diameter (P = 0.0350), differentiation (P = 0.0038), lymphatic metastasis (P = 0.0119), distant metastasis (P < 0.0001), TNM stage (P = 0.0002), and depth of invasion (P = 0.001) in patients with CRC. The summary area under the curve (AUC) of circRNA for the discriminative efficacy between patients with and without CRC was estimated to be 0.79, corresponding to a weighted sensitivity of 0.77 [95% confidence interval (CI): 0.74–0.79], specificity of 0.67 (95%CI: 0.64–0.70), and diagnostic odds ratio (DOR) of 7.52 (95%CI: 4.66–12.12). Survival analysis showed that highly expressed circRNAs were correlated with significantly worse overall survival (OS) [hazard ratio (HR) = 2.66, 95%CI: 2.03–3.50, P = 0.000; X2 = 4.34, P = 0.740, I2 = 0.0%], whereas lower expression of circRNAs was associated with prolonged OS (weighted HR = 0.30, 95%CI: 0.17–0.53, P = 0.000; X2 = 1.34, P = 0.909, I2 = 0.0%). Stratified analysis in circRNA expression status, and test matrix also showed robust results. Conclusion Abnormally expressed circRNAs may be auxiliary biomarkers facilitating CRC diagnosis, and promising prognostic biomarkers in predicting the survival of CRC patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer

Zhang

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Comparison of concentration of studied proteins between margin and tumor tissue GDF-15 levels are increased in various pathological conditions, such as inflammation and injuries. They are also up-regulated in digestive system tumours including CRC, gastrointestinal cancer, pancreatic cancer, esophageal carcinoma, and liver cancer [13].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the associations between GDF-15, OPG, and IL-15 levels in CRC: preliminary results

Robotycka

Mielcarska

Dawidowicz

et al. 2022

Medical Research Journal

View full text Add to dashboard Cite

Introduction: Osteoprotegerin (OPG), , and Growth/Differentiation are all proven to take part in the processes associated with colorectal carcinoma (CRC) including tissue remodeling, inflammation modulation, and metastasis.Aim of the study: To investigate the concentrations of GDF-15, OPG and IL-15 in tumor and margin tissues of CRC in relation to clinicopathological features of patients. Material and methods:The study used 50 specimens of tumor and tumor-free margin tissues obtained from CRC patients. To determine the GDF-15, OPG and IL-15 concentrations commercially available enzyme-linked immunosorbent assay (ELISA) kits were used.Results: Concentrations of GDF-15, OPG and IL-15 were significantly higher in the tumor in comparison with the margin. The tumor levels of GDF-15 were positively associated with those of OPG and IL-15, while tumor levels of OPG correlated positively with those of IL-15. There was no association between levels of investigated molecules and clinical features of patients. Conclusions:The levels of GDF-15, OPG and IL-15 are elevated in patients suffering from CRC. More studies are needed to establish a specific role of these cytokines in the development, tumor growth, progression, and prognosis of CRC and to examine their role as possible CRC treatment candidates.

show abstract

“…It is significantly increased in various pathological conditions, including inflammation and cancer. Several groups have proposed it as a biomarker in prostatic, colorectal, hepatocellular, and pancreatic carcinomas, among other malignancies [5,41]. Therefore, it is clear from the existing evidence that GDF-15 may not be specific for any single cancer type.…”

Section: Scribedmentioning

confidence: 99%

Growth Differentiation Factor-15 as a candidate biomarker in gynecologic malignancies: A meta-analysis

Roy¹,

Modi²,

Khokhar³

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Growth Differentiation Factor-15 (GDF-15) has emerged as a novel marker in gynecological cancers. But its suitability in clinical diagnostics is yet to be recognized. Materials and methods: We sorted out eligible studies from multiple online databases like Pubmed, Cochrane, ClinicalTrials.gov, Google Scholar, Web of Science, Embase, Scopus, LILACS, and Opengrey. The terms used were 'Growth Differentiation Factor-15', 'GDF-15', 'Macrophage Inhibitory Cytokine-1', 'MIC-1', 'Ovarian cancer', 'Ovarian carcinoma', 'Endometrial cancer', 'Endometrial carcinoma', 'Uterine cancer', 'Uterine Carcinoma', 'Cervical cancer', 'Cervical carcinoma', 'diagnosis', 'sensitivity', 'specificity', 'prognosis', and 'outcome'. Of the full-text, potentially eligible records, six were found eligible for inclusion into our meta-analysis. Studies were selected only if the diagnosis was proven by pathology, cases recruited were those without any prior treatment, sufficient diagnostic accuracy data were present for GDF-15 in gynecological cancers, and ethical approval was taken from Institutional Ethics Committee. Nonclinical research and animal studies were excluded. We took the assistance of the Rayyan QCRI software for the screening and selection process. We conducted the study following Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines and used Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) to assess the risk of bias. The protocol was registered at PROSPERO, registration number CRD42019130097. Results: We extracted diagnostic accuracy data from the articles and evaluated the role of GDF-15 by pooling the sensitivity, specificity, and diagnostic odds ratio (DOR) and plotting a summary receiver operating characteristic (SROC) curve. Since there was heterogeneity across the studies, the random-effects model was employed to carry out the integration. The meta-analysis showed that GDF-15 has a pooled DOR of 12.74 at 80.5% sensitivity and 74.1% specificity, with an area under the curve (AUC) of 0.84. Conclusion: Our analysis suggests that GDF-15 may be a useful candidate marker to differentiate malignant from non-malignant tumors of the female reproductive system.

show abstract

Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis

Cited by 16 publications

References 32 publications

A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer

A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer

Evaluation of the associations between GDF-15, OPG, and IL-15 levels in CRC: preliminary results

Growth Differentiation Factor-15 as a candidate biomarker in gynecologic malignancies: A meta-analysis

Contact Info

Product

Resources

About